State pharmacy board vs FDA: who oversees compounding
Compounding has two overseers. Knowing which one does what makes the regulatory news much easier to read.
TL;DR
- State pharmacy boards license and inspect 503A compounding pharmacies as part of routine pharmacy oversight.
- The FDA sets federal rules — including the bulk-substance lists — and inspects 503B outsourcing facilities directly.
- State board actions affect one pharmacy; FDA actions can affect the whole compounding landscape.
What it is
A state pharmacy board is the agency in each state that licenses pharmacists and pharmacies, sets practice rules, and runs inspections. The FDA is the federal agency that regulates drug manufacturing, drug approval, and certain categories of compounding under Sections 503A and 503B of the Food, Drug, and Cosmetic Act. The two are not redundant — they cover different layers of the same system.
How it works
Think of compounding oversight like a tailor’s shop inside a regulated industry. The state board is the local inspector who checks that the shop is properly licensed, that the tailors are credentialed, that the tools are clean, and that the day-to-day work meets standards. The FDA is the federal authority that sets which fabrics the tailor is allowed to use, what the labels must say, and which kinds of large-scale tailor shops (503B outsourcing facilities) need to operate like manufacturers. Most patients interact with the state-board layer through their pharmacy; they interact with the FDA layer when federal news shifts what can be compounded (FDA Compounding Q&A, 2024).
Who asks about it
People come to this question after seeing a regulatory headline and trying to figure out whether it changes their access. The honest answer: it depends which agency moved. State actions are usually pharmacy-specific. FDA actions can reshape whole categories.
What the research says
Section 503A of the Food, Drug, and Cosmetic Act defines the legal frame for traditional compounding pharmacies and grants them limited exemptions from FDA new-drug approval — provided they meet specific conditions, including a valid prescription for an identified patient (FDA Section 503A, 2024). The FDA maintains the bulk-substance lists (Category 1, Category 2) that determine which non-monograph substances may be used in 503A compounding. State pharmacy boards add their own rules on top — practice standards, licensure, and pharmacy-level inspections.
What to know before considering it
If your medication is from a 503A pharmacy, the pharmacy’s day-to-day operation is licensed and inspected by its state board, and its eligible compounding categories are set by federal law and FDA policy. A pharmacy can be in good state-board standing and still be unable to compound a specific peptide because the FDA classifies that ingredient as Category 2.
The Halftime POV
The “who regulates what” question turns out to be one of the most useful for reading peptide regulatory news. Two overseers, two scopes, one shared goal. That is the frame.
Related reading:
FAQ
Q: Who regulates compounding pharmacies? A: Compounding has two overseers. State pharmacy boards license and inspect 503A pharmacies as part of regular pharmacy regulation. The FDA sets federal rules through the Food, Drug, and Cosmetic Act — including which bulk substances can be compounded — and inspects 503B outsourcing facilities directly.
Q: Does the FDA inspect 503A pharmacies? A: The FDA can inspect 503A pharmacies for specific federal violations — adulterated or misbranded drugs, unsafe ingredients, sale across state lines beyond limits — but routine pharmacy oversight is a state pharmacy board responsibility.
Q: Why does this matter for patients? A: Knowing who oversees what helps you read regulatory news correctly. A state board action affects one pharmacy. An FDA decision — like reclassifying which peptides can be compounded — affects the whole 503A landscape.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
